Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry
ConclusionsLong-term survival is achievable in patients with low-volume biphasic mesothelioma after complete macroscopic cytoreduction. Biphasic peritoneal mesotheliomas should not be considered as an absolute contraindication for CRS/HIPEC if there is low-volume disease and if complete cytoreduction can be achieved.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Mesothelioma | Peritoneal Cancer